Login / Signup

Reply to Wang et al.: Tocilizumab treatment should be used in a timely manner, at suitable dose, and in suitable patients.

Xiaoling XuMingfeng HanTiantian LiWei SunDongsheng WangBinqing FuYonggang ZhouXiaohu ZhengYun YangXiuyong LiXiaohua ZhangAijun PanHaiming Wei
Published in: Proceedings of the National Academy of Sciences of the United States of America (2020)
Keyphrases
  • end stage renal disease
  • ejection fraction
  • newly diagnosed
  • rheumatoid arthritis
  • patient reported outcomes
  • patient reported